Contemporary Approaches to Melanoma Detection and Advanced Therapeutics
Year: 2026
Type: article
Abstract: Cutaneous melanoma is a highly aggressive form of skin cancer, which accounts for up to 80% of skin cancer-related deaths worldwide. Despite significant advances in melanoma treatment for the past 15 years, the established therapies with BRAFi/MEKi and immunotherapy with checkpoint inhibitors (ICIs) suffer from acquired and intrinsic resistance, as well as adverse side effects. Due to the limited specificity of currently employed diagnostic probes, an urgent need exists for a new generation of molecular probes that can selectively target malignant melanoma lesions and provide adequate information on the stage and progress of the disease. This review highlights the most recent advances made in 2025–2026 in melanoma treatment and detection. In the first section, new selective PET tracers and fluorescent probes for diagnosis and staging of melanoma are discussed. The second section discusses diverse approaches to melanoma treatment, such as novel small-molecule drugs capable of overcoming resistance to BRAFi/MEKi and increased sensitivity to ICIs, multi-action nanoformulations, biocompatible microneedle patches for efficient transdermal drug delivery, and novel immunotherapy approaches. Together, this review illustrates that further research in the treatment and diagnosis of melanoma is moving toward new molecular targets, efficient drug combinations, and patient-specific therapy.
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: cutaneous melanoma, melanoma detection, PET radiotracer, fluorescent probes, melanoma staging, BRAF inhibitor resistance, MEK inhibitor resistance, immune checkpoint inhibitors, immunotherapy, small molecule drugs, nanoformulations, microneedle patch, transdermal drug delivery, molecular probes
Open Access status: gold
Estimated APC paid: $3,499
Funder: Russian Science Foundation
Award: G9001398293
OpenAlex ID: W7236741817
